The target audience for this activity is clinicians who treat patients with gastrointestinal cancers (gastroenterologists, hepatologists, medical oncologists, surgical oncologists, GI surgeons, oncology nurses and nurse practitioners, interventional radiologists, oncology pharmacists).

• Evaluate best available evidence regarding treatment of GI cancer
• Assess the clinical implications of emerging clinical trial data regarding treatment approaches for patients with GI cancer
• Develop strategies to address complicated GI cancer cases

In support of improving patient care, this activity has been planned and implemented by University of Nebraska Medical Center Bio Ascend. University of Nebraska Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The University of Nebraska Medical Center designates this live activity for a maximum of 1 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

As a jointly accredited provider, the University of Nebraska Medical Center (UNMC) ensures accuracy, balance, objectivity, independence, and scientific rigor in its educational activities and is committed to protecting learners from promotion, marketing, and commercial bias. All faculty, planners, and others in a position to control continuing education content participating in an accredited continuing education activity are required to disclose all financial relationships with ineligible companies. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. The accredited provider is responsible for mitigating all relevant financial relationships in accredited continuing education.  Disclosure of these commitments and/or relationships is included in these activity materials so that participants may formulate their own judgments in interpreting its content and evaluating its recommendations.

This activity may include presentations in which faculty may discuss off-label and/or investigational use of pharmaceuticals or instruments not yet FDA-approved. Participants should note that the use of products outside currently FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for FDA-approved indications.  All materials are included with the permission of the faculty. The opinions expressed are those of the faculty and are not to be construed as those of UNMC or Bio Ascend.